W E Robinson

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase
    W E Robinson
    Department of Pathology, University of California, Irvine 92697 4800, USA
    Mol Pharmacol 50:846-55. 1996
  2. ncbi request reprint L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350)
    W E Robinson
    Department of Pathology, University of California, Irvine, 92697 4800, USA
    Antiviral Res 39:101-11. 1998
  3. ncbi request reprint Natural selection results in conservation of HIV-1 integrase activity despite sequence variability
    R Reinke
    Department of Microbiology and Molecular Genetics, University of California, Irvine, 92967-4800, USA
    AIDS 15:823-30. 2001
  4. pmc Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid
    Deborah J Lee
    Department of Pathology, D440 Med Sci I, University of California, Irvine, CA 92697 4800, USA
    J Virol 78:5835-47. 2004
  5. ncbi request reprint Anti-HIV-1 activity of indolicidin, an antimicrobial peptide from neutrophils
    W E Robinson
    Department of Pathology, University of California, Irvine 92697 4800, USA
    J Leukoc Biol 63:94-100. 1998
  6. ncbi request reprint Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro
    R J Essey
    Department of Pathology, University of California, 92697-4800, Irvine, CA, USA
    Antiviral Res 51:189-202. 2001

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase
    W E Robinson
    Department of Pathology, University of California, Irvine 92697 4800, USA
    Mol Pharmacol 50:846-55. 1996
    ..These results indicate that the dicaffeoylquinic acids as a class are potent and selective inhibitors of HIV-1 IN and form important lead compounds for HIV drug discovery...
  2. ncbi request reprint L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350)
    W E Robinson
    Department of Pathology, University of California, Irvine, 92697 4800, USA
    Antiviral Res 39:101-11. 1998
    ....
  3. ncbi request reprint Natural selection results in conservation of HIV-1 integrase activity despite sequence variability
    R Reinke
    Department of Microbiology and Molecular Genetics, University of California, Irvine, 92967-4800, USA
    AIDS 15:823-30. 2001
    ....
  4. pmc Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid
    Deborah J Lee
    Department of Pathology, D440 Med Sci I, University of California, Irvine, CA 92697 4800, USA
    J Virol 78:5835-47. 2004
    ..Thus, IN mutations conferring resistance to the diketo acids can yield integration defects, attenuated catalysis in vitro, and cross-resistance to l-chicoric acid...
  5. ncbi request reprint Anti-HIV-1 activity of indolicidin, an antimicrobial peptide from neutrophils
    W E Robinson
    Department of Pathology, University of California, Irvine 92697 4800, USA
    J Leukoc Biol 63:94-100. 1998
    ....
  6. ncbi request reprint Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro
    R J Essey
    Department of Pathology, University of California, 92697-4800, Irvine, CA, USA
    Antiviral Res 51:189-202. 2001
    ..These results suggest that polyI-polyC(12)U should be re-evaluated as a potential adjunct therapy in patients who have failed current anti-retroviral therapeutic regimens...